Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Longitudinal Cohort Study of Aplastic Anemia Across the Disease Course

NCT07930793 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07930793 Recruiting Observational 9,999 participants (estimated) Started 2012 1 site

Follow this trial by email Email me the PDF

Get the NCT07930793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Recruiting, started January 2012. Observational study, 9,999 participants (estimated). Lead sponsor Institute of Hematology & Blood Diseases Hospital, China; China. Primary measures: Hematologic response; Clonal evolution and 1 more.

How it compares

68 similar trials: same condition (Anemia, Aplastic) and phase

Enrollment

This trial
9,999
Middle half
36 to 700
Median
100
Trials with a value
64

Months from start to completion

This trial
708
Middle half
34 to 81.1
Median
57
Trials with a value
66

Sites

This trial
1
Middle half
1 to 1
Median
1
Trials with a value
58
Posted results or a linked paper 22% 15 of 68 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Longitudinal Cohort Study of Aplastic Anemia Across the Disease Course
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2012
Completion date
December 31, 2070
Enrollment
9,999 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Anemia, Aplastic

Registry terms: aplastic anemia, clonal hematopoiesis, immunosuppressive therapy

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Healthy volunteers
No
Study type
Observational
Sites
1
Countries
China
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
TRACE-AA A combined retrospective and prospective observational follow-up
Show registry wording

1. Describe real-world treatment patterns and clinical outcomes in AA, including IST, HSCT, and other therapies.
2. Evaluate treatment-related adverse events and safety, particularly complications of ATG/ALG-based IST and HSCT.
3. Characterize longitudinal hematopoietic and immune reconstitution after drug therapy or HSCT, including immune-cell subsets, clonal T cells, immune biomarkers, and hematopoietic recovery.
4. Estimate the cumulative incidence and trajectories of clonal hematopoiesis after IST, including cytogenetic and molecular abnormalities and PNH clones.
5. Assess prognosis, including treatment discontinuation, relapse, clonal evolution, quality of life, and long-term survival.

Primary endpoints

Registered primary outcome measures; 3 primary.

Registered primary endpoints
Measure Time frame
Hematologic response Assessments will be conducted at baseline, 6 months, 12 months, and 24 months after treatment, as well as at study completion, with an average interval of approximately 1 year.
Show registry wording

Hematologic response contains improvements in hemoglobin level, platelet count and neutrophil count.

Clonal evolution Assessments will be conducted at baseline, 6 months, 12 months, and 24 months after treatment, as well as at study completion, with an average interval of approximately 1 year.
Show registry wording

Progression to paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, or acute myeloid leukemia.

Treatment related adverse events Within 10 years after allo-HSCT; within 6 months after IST
Show registry wording

The main treatment modalities include allogeneic hematopoietic stem cell transplantation (allo-HSCT) and intensive immunosuppressive therapy (IST). Use Common Terminology Criteria for Adverse Events (CTCAE) Version 6 to assess the adverse event

Lead sponsor's other trials

Institute of Hematology & Blood Diseases Hospital, China, most recent start first.

Similar trials

Same condition (Anemia, Aplastic) and phase, most recent start first.